Medical News / ERS 2020: Monotherapy LAMA is Over-Used, Linked to Asthma Exacerbation Risk

Long-acting muscarinic antagonists (LAMA) are frequently prescribed out of step with guidance for treating patients with asthma, according to a new study. In new data presented virtually during the European Respiratory Society (ERS) 2020 Congress this week, a team of investigators from the Netherlands and Belgium showed monotherapy LAMA is prevalent among nearly 40% of observed users with asthma—despite its indication being for add-on use. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

According to new phase 3 data presented at the American Academy of Ophthalmology 2021 Meeting, brolucizumab ... read more
In an interview with HCPLive, Veeral Sheth, MD, Director of Clinical Trials, University Retina, discussed the ... read more
Access to US ophthalmology clinical trial sites may differ by region, according to new study findings ... read more
Although there are questions on the rationale behind step therapy, particularly for neovascular (wet) age-related macular ... read more